文献
J-GLOBAL ID:201702236495393193
整理番号:17A1421629
関節リウマチ(経口戦略)患者におけるメトトレキセートとトファシチニブ単独療法,メトトレキセートとトファシチニブとアダリムマブの有効性と安全性:相3b/4,二重盲検,頭-頭,無作為化対照試験【Powered by NICT】
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
著者 (15件):
Fleischmann Roy
(University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, USA)
,
Mysler Eduardo
(Organizacion Medica de Investigacion, Buenos Aires, Argentina)
,
Hall Stephen
(Department of Medicine, Monash University, Cabrini Health, Malvern, VIC, Australia)
,
Kivitz Alan J
(Altoona Center for Clinical Research, Duncansville, PA, USA)
,
Moots Robert J
(Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK)
,
Luo Zhen
(Pfizer Inc, Shanghai, China)
,
DeMasi Ryan
(Pfizer Inc, Collegeville, PA, USA)
,
Soma Koshika
(Pfizer Inc, Groton, CT, USA)
,
Zhang Richard
(Pfizer Inc, New York, NY, USA)
,
Takiya Liza
(Pfizer Inc, Collegeville, PA, USA)
,
Tatulych Svitlana
(Pfizer Inc, Groton, CT, USA)
,
Mojcik Christopher
(Pfizer Inc, New York, NY, USA)
,
Krishnaswami Sriram
(Pfizer Inc, Groton, CT, USA)
,
Menon Sujatha
(Pfizer Inc, Groton, CT, USA)
,
Smolen Josef S
(Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria)
資料名:
Lancet
(Lancet)
巻:
390
号:
10093
ページ:
457-468
発行年:
2017年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)